

The logo for the 2nd Global Liver Health Forum is a stylized, orange-to-red gradient shape resembling a liver. It features a large white number '2' on the left, followed by the text 'nd GLOBAL LIVER HEALTH FORUM' in white, stacked vertically.

**2<sup>nd</sup> GLOBAL  
LIVER  
HEALTH  
FORUM**

# **SCIENCE TO ADVANCE LIVER HEALTH**

**Friday, 22<sup>nd</sup> October 2021**

**Virtual Forum**

**SANOFI** 



# SUMMARY



Welcome letter ..... 4

Agenda..... 5

## SPEAKER BIOGRAPHIES

Professor Jian-Gao Fan ..... 6

Professor Chavdar Pavlov..... 7

Professor Gert Fricker ..... 8

Professor Alexander Nersesov..... 9

Ms Donna Cryer..... 10

Doctor Yiwen Shi ..... 11



# WELCOME LETTER

Dear colleague,

It gives us great pleasure to welcome you to the third and final webinar of the **2<sup>nd</sup> Global Liver Health Forum!** This meeting follows on from the success of the first two webinars in this series, the first of which took place in June of this year and the second more recently on 8<sup>th</sup> October. This webinar will also feature a live panel discussion moderated by Donna Cryer from the Global Liver Institute (GLI) – a global patient advocacy group promoting innovation across the spectrum of liver health. In this final webinar, we aim to continue raising awareness of the key factors influencing NAFLD and liver health management and discuss vital paradigm shifts in this field.

During this final session of the webinar series, we will discuss liver-directed hepatoprotective treatment options for NAFLD/MAFLD and the importance of early intervention. We will also explore new perspectives on the mechanism of action of essential phospholipids and the effects of essential phospholipid treatment on liver health.

As per the previous webinars, the use of the latest technology ensures the 2<sup>nd</sup> Global Liver Health Forum will continue to be dynamic, interactive and will allow us to gain perspectives from participants across the world. This event will facilitate a powerful information exchange that will allow us to define best practices to ensure our patients get the best care. We encourage you to take advantage of the opportunity to ask questions throughout the meeting which the experts will answer during the panel discussion. We hope that you and your peers from all over the world will enjoy this insightful meeting.

We would like to express our sincere gratitude to the people who made this meeting possible. We extend a special thanks to our faculty, who have dedicated their time to sharing their knowledge and passion with us all. We are sure that this webinar will provide an engaging and informative conclusion to the 2<sup>nd</sup> Global Liver Health Forum.

Yours sincerely,

**Etienne Pouteau**

Global Medical Head for Digestive Health,  
Sanofi Consumer Healthcare

**Branko Popovic**

Global Medical Lead for Digestive Health,  
Sanofi Consumer Healthcare

# AGENDA

Friday, 22<sup>nd</sup> October 2021

TIME CET (UTC+2)	TOPICS	SPEAKER
10:00–10:10	Welcome and introduction	Sanofi and Professor J Fan (Chair; CHN)
Session 1		
10:10–10:25	Putting MAFLD into perspective – liver-directed hepatoprotective treatment options	Professor J Fan (CHN)
10:25–10:40	Hepatic steatosis in MAFLD – importance of early intervention	Professor C Pavlov (RUS)
10:40–10:45	Break	
Session 2		
10:45–11:00	Essential phospholipids – new perspectives on the MoA	Professor G Fricker (GER)
11:00–11:15	Comorbidities in NAFLD – metabolic syndromes and beyond, REPAIR study insights	Professor A Nersesov (KAZ)
11:15–11:30	Break	
Panel Discussion		
11:30–11:40	Efforts for early detection and screening of NAFLD, and global burden of NAFLD	Ms D Cryer (GLI President; USA)
11:40–12:55	Discussion	All Panelists, Dr Y Shi (CHN)
12:55–13:00	Concluding remarks	Ms D Cryer (USA)



## Professor Jian-Gao Fan

Center for Fatty Liver and the Department of Gastroenterology at Xinhua Hospital, Shanghai Key Laboratory of Pediatric Gastroenterology and Nutrition, Shanghai, China

Professor Fan is Professor and Director of the Center for Fatty Liver and the Department of Gastroenterology at Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, China. He is also the Principal Investigator of the Shanghai Key Laboratory of Pediatric Gastroenterology and Nutrition as well as Editor-in-Chief of the Chinese *Journal of Practical Hepatology*.

Professor Fan is a member of the editorial board of over 20 journals, and a peer-reviewer for several other major journals. His roles include clinical care, research and teaching of gastroenterology and hepatology; his main research interests are in the fields of metabolic syndrome and chronic liver diseases.

### Putting MAFLD into perspective – liver-directed hepatoprotective treatment options

#### What will you learn:

- Conclusions from the TOWARDS 1 study – understanding a novel fibrosis diagnostic method and the impact of metabolic dysfunction in patients with MAFLD
- How important is pharmacotherapy for patients with MAFLD?
- A review of hepatoprotective treatment options as adjunctive therapy for MAFLD
- What are the unmet therapeutic needs for your patients with MAFLD?



## Professor Chavdar Pavlov

Department of Therapy and Center for Evidence-Based Medicine, 'Sechenov' First Moscow State Medical University, Russia

Professor Pavlov is Head of the Department of Therapy and Head of the Center for Evidence-Based Medicine at 'Sechenov' First Moscow State Medical University, Russia. He is also Vice-President for foreign relations with the Russian Scientific Liver Society and Vice-President of the Russian Scientific Society for the Study of Microbiome.

Professor Pavlov is also an editor for the Cochrane Hepato-Biliary Group, providing guidance to authors and ensuring the quality of their work. He has a particular research interest in fatty liver diseases and is the author of over 230 publications in Russian and English.

### Hepatic steatosis in MAFLD – importance of early intervention

#### What will you learn:

- Diagnostic methods for early detection of hepatic steatosis
- What is the impact of essential phospholipids on hepatic steatosis?
- Can early intervention improve long-term clinical outcomes for patients with MAFLD?



## Professor Gert Fricker

Institute of Pharmacy and Molecular Biotechnology, University of Heidelberg, Germany

Professor Fricker is a Director at Institute of Pharmacy and Molecular Biotechnology at the University of Heidelberg and a Partner at Heidelberg Delivery Technologies Heidelberg, Germany. He has also been working as a visiting Principal Investigator at the Mount Desert Island Biological Laboratory (USA) since 1985.

Professor Fricker is a biochemist by training and a well-known expert in the field of brain drug delivery and oral delivery using phospholipid drug delivery systems. He also organises the annual Barrier and Transporter meeting in Bad Herrenalb.

### Essential phospholipids – new perspectives on the MoA

#### What will you learn:

- What is the mechanism of action of essential phospholipids?
- Molecular effects of essential phospholipids on hepatic cells – anti-apoptotic and effects on cell membrane transport proteins



## Professor Alexander Neresov

Department of Gastroenterology, National Research Institute of Cardiology and Internal Medicine, Kazakhstan

Professor Neresov is currently the Head of the Department of Gastroenterology and Hepatology at the National Research Institute of Cardiology and Internal Medicine, Kazakhstan. Since 2007, he has been the President of the Kazakh Association for the Study of the Liver.

Professor Neresov has professional affiliations with several professional organisations including European Association for the Study of the Liver, The Asian Pacific Association for the Study of the Liver and The Japanese Society of Hepatology. His main clinical and research interests are in chronic viral hepatitis and liver cirrhosis complications. He is the author and co-author of approximately 120 publications in local and international journals, provides clinical supervision and serves as a principal organiser of the local and international conferences on gastroenterology and hepatology in Kazakhstan.

### Comorbidities in NAFLD – metabolic syndromes and beyond, REPAIR study insights

#### What will you learn:

- How important is the MAFLD concept and metabolic comorbidities?
- REPAIR study – rationale and study design
- Overview of the REPAIR study results – effects of essential phospholipids on liver health and what this could mean for patients with MAFLD





**Ms Donna Cryer**

Global Liver Institute, Washington, DC, USA

Ms Cryer is the Founder, President and Chief Executive Office of the Global Liver Institute: the only patient-driven liver health non-profit operative in the USA and Europe. She has developed a number of patient engagement programmes and activities designed to empower patients and promote improved health outcomes for patients with liver diseases across a spectrum of origins.



**Doctor Yiwen Shi**

Xinhua hospital affiliated to Shanghai Jiao Tong University School of Medicine, China

Dr Shi is a postdoc the Xinhua hospital affiliated to Shanghai Jiao Tong University School of Medicine, China. Her research interests are in NASH, metabolic disorder disease and viral hepatitis. In addition to participating in several clinical trials of novel therapeutics for NASH, Dr Shi has published her work in a number of journals, including *World Journal of Gastroenterology* and *Journal of Clinical and Translational Hepatology*.

### Panel discussion

---

#### Key objectives:

- Raising NAFLD disease awareness
- Defining pathways for early detection and clinical care

**2<sup>nd</sup> GLOBAL  
LIVER  
HEALTH  
FORUM**

**SANOFI** 

**MAT-GLB-2103108**  
**Date of approval: October 2021**